1. Scrip

Coronavirus Update: As Pfizer/BioNTech Begin Omicron Vaccine Tests, Regulators Want To Explore Multivalent Route

Plus: One Step Forward For Veklury, Two Steps Back For REGEN-COV

 
• By Scrip Team

Pfizer explores options for new vaccine update, Veklury expands to non-hospitalized patients but Regeneron and Lilly therapies stopped in face of Omicron efficacy drop-off.  

Wuhan 2022
Wuhan, China: two years on from the initial outbreak, China is preparing for New Year's celebrations and the Winter Olympics, but is still dealing with SARS-CoV2. • Source: Getty Images

Pfizer and BioNTech have launched the first clinical trial of an Omicron version of their COVID-19 vaccine Comirnaty that will study its use both as a booster and in previously unvaccinated people.

Omicron is now the predominant SARS-CoV-2 variant in many parts of the world, and despite its generally less severe symptoms, has been shown to partially evade

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Trump’s executive order more rhetoric than action; industry grapples with Trump pricing plan; Hengrui set for this year’s biggest IPO; Sanofi’s exec’s advice to biotechs; and biotech deal return on investment falls.